Hydroflumethiazide

CAS: 135-09-1

Ref. 3D-AAA13509

Información del producto

• Nombre: Hydroflumethiazide
• Sinónimos: 1,1-Dioxo-6-(trifluoromethyl)-1,2,3,4-tetrahydro-1λ6,2,4-benzothiadiazine-7-sulfonamide, 1,1-Dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1λ6,2,4-benzothiadiazine-7-sulfonamide, 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide, 3,4-Dihydro-6-(trifluoromethyl)-2H-1,2,4-, 3,4-Dihydro-6-trifluoromethyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide, 3,4-Dihydro-6-trifluoromethyl-2H-1,2,4-benzothiazide-7-sulfonamide 1,1-dioxide, 3,4-Dihydro-6-trifluoromethyl-7-sulfamoylbenzo-1,2,4-thiadiazine 1,1-dioxide, 3,4-Dihydro-7-sulfamoyl-6-trifluoromethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide, 3,4-Dihydro-7-sulfamyl-6-trifluoromethyl-1,2,4-benzothiadiazine 1,1-dioxide, 3,4-Dihydro-7-sulfamyl-6-trifluoromethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide, 6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide, 6-Trifluoromethyl-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide, 6-Trifluoromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide, 7-Sulfamyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide, Benzothiodiazine(2H-1,2,4)-7-Sulfonamide, 3,4-Dihydro-6-Trifluoromethyl)-1,1-Dioxide, Bristab, Bristurin, Di-Ademil, Dihydroflumethiazide, Diucardin, Diumide K, Diuredemina, Diurometon, Elodrine, Finuret, Flutizide, Glomerulin, Hidroalogen, Hidroflumetiazid, Hidroflumetiazida, Hydol, Hydrenox, Hydroflumethiazid, Leodrine, Metflorylthiazidine, Methforylthiazidine, NaClex, NaClex (Glaxo), Nsc 44627, Olmagran, Rodiuran, Rontyl, Saluron, Salutensin, Sisuril, Spandiuril, Trifluoromethylhydrothiazide, Vergonil

Descripción

Hydroflumethiazide is a diuretic drug that is used to treat high blood pressure, heart failure, and edema. It decreases the production of aqueous humor by the eye, thereby decreasing intraocular pressure. Hydroflumethiazide also inhibits sodium reabsorption in the loop of Henle and helps to control hypertension. The drug increases renal excretion of water and electrolytes, which can lead to dehydration. Hydroflumethiazide has been shown to have an adverse effect on cardiovascular function due to its ability to inhibit ATP channels in cardiac cells and interfere with glomerular filtration rate (GFR). It has also been found to increase matrix metalloproteinases (MMP) activity in inflammatory bowel disease patients.

• Marca: Biosynth

Propiedades químicas

• Peso molecular: 331.29 g/mol
• Fórmula: C₈H₈F₃N₃O₄S₂
• Pureza: Min. 95%